Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Recruiting · NCT06472388 · Registry updated 2024-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, adenoma, carcinoid tumor, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2024-06-25 | NCT06472388 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AC Camargo Cancer Center | 12 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| AC Camargo Cancer Center | São Paulo | Brazil | 1 |
| AC Camargo Cancer Center | São Paulo | Brazil | 2 |